彩色多普勒超声检查评价乳腺癌新辅助化疗疗效及复发的价值
|
摘要
目的探讨彩色多普勒超声检查评价乳腺癌患者的新辅助化疗疗效及复发的价值。方法选取150例行乳腺癌改良根治术的患者,所有患者均接受了新辅助化疗和彩色多普勒超声检查。统计新辅助化疗前后彩色多普勒超声检查结果(病灶的数量、大小、边界、内部回声及后方回声等)。以病理结果为金标准,分析彩色多普勒超声检查评价乳腺癌患者的新辅助化疗疗效及复发的价值。结果彩色多普勒超声检查结果显示,新辅助化疗后患者病灶的长、宽、高、面积、体积均明显小于化疗前(P<0.01);新辅助化疗前后患者病灶的边界清晰情况、内部回声情况、后方回声情况比较,差异均有统计学意义(P<0.01);彩色多普勒超声检查评价新辅助化疗疗效的结果显示,有效124例,无效26例;与病理结果对照,其诊断的灵敏度为89.57%,符合率为68.67%;术后6个月复查时彩色多普勒超声检查结果显示,新辅助化疗有效的患者中,复发32例,未复发83例;与病理结果对照,其诊断的灵敏度为60.00%。结论彩色多普勒超声检查可提供客观的乳腺癌患者新辅助化疗前后病灶变化的参考数据,对评价乳腺癌患者的新辅助化疗疗效具有较高的价值,并可较好地评估复发情况。
Objective To investigate the value of color Doppler ultrasound in evaluating the efficacy of neoadjuvant chemotherapy and recurrence in breast cancer patients. Method 150 patients undergoing modified radical mastectomy for breast cancer were selected. All patients underwent neoadjuvant chemotherapy and color Doppler ultrasound. Color Doppler ultrasound was used to observe the number, size, boundary, internal echo and posterior echo of the lesion before and after neoadjuvant chemotherapy. The value of color Doppler ultrasound in evaluating the efficacy of neoadjuvant chemotherapy and recurrence in breast cancer patients was analyzed based on pathological results. Result The results of color Doppler ultrasound showed that the length, width, height, area and volume of lesions after neoadjuvant chemotherapy,were significantly smaller than those before neoadjuvant chemotherapy(P<0.01). There were significant differences in boundary clarity, internal echo and posterior echo before and after neoadjuvant chemotherapy(P<0.01). The results of color Doppler ultrasound in evaluating the efficacy of neoadjuvant chemotherapy showed that 124 cases were effective and 26 cases were ineffective. Compared with pathological diagnosis, the sensitivity of diagnosis was 89.57%, and the coincidence rate was 68.67%. The results of color Doppler ultrasound showed that among the patients with effective neoadjuvant chemotherapy 32 cases had recurrence and 83 cases had no recurrence in 6 months after operation. Compared with pathological diagnosis, the diagnostic sensitivity was 60.00%. Conclusion Color Doppler ultrasound can provide objective reference data of lesion changes in breast cancer patients before and after neoadjuvant chemotherapy. It has high value in evaluating the efficacy of neoadjuvant chemotherapy in breast cancer patients, and can better predict the recurrence.
Objective To investigate the value of color Doppler ultrasound in evaluating the efficacy of neoadjuvant chemotherapy and recurrence in breast cancer patients. Method 150 patients undergoing modified radical mastectomy for breast cancer were selected. All patients underwent neoadjuvant chemotherapy and color Doppler ultrasound. Color Doppler ultrasound was used to observe the number, size, boundary, internal echo and posterior echo of the lesion before and after neoadjuvant chemotherapy. The value of color Doppler ultrasound in evaluating the efficacy of neoadjuvant chemotherapy and recurrence in breast cancer patients was analyzed based on pathological results. Result The results of color Doppler ultrasound showed that the length, width, height, area and volume of lesions after neoadjuvant chemotherapy,were significantly smaller than those before neoadjuvant chemotherapy(P<0.01). There were significant differences in boundary clarity, internal echo and posterior echo before and after neoadjuvant chemotherapy(P<0.01). The results of color Doppler ultrasound in evaluating the efficacy of neoadjuvant chemotherapy showed that 124 cases were effective and 26 cases were ineffective. Compared with pathological diagnosis, the sensitivity of diagnosis was 89.57%, and the coincidence rate was 68.67%. The results of color Doppler ultrasound showed that among the patients with effective neoadjuvant chemotherapy 32 cases had recurrence and 83 cases had no recurrence in 6 months after operation. Compared with pathological diagnosis, the diagnostic sensitivity was 60.00%. Conclusion Color Doppler ultrasound can provide objective reference data of lesion changes in breast cancer patients before and after neoadjuvant chemotherapy. It has high value in evaluating the efficacy of neoadjuvant chemotherapy in breast cancer patients, and can better predict the recurrence.
引文
[1]郑紫昊,邹世芳,徐雨婷,等.晚期HR(+)、HER-2(-)乳腺癌内分泌治疗的研究进展[J].医学综述,2018,24(3):507-511.
[2]杨月杰.超声造影技术在乳腺癌新辅助化疗疗效评估中的应用分析[J].山西医药杂志,2019,48(2):40-41.
[3]贾志莺,张连花,马富成.超声联合技术在乳腺癌新辅助化疗疗效评价中的应用价值[J].医学影像学杂志,2017,27(9):1723-1725.
[4]Ogston KN,Miller ID,Payne S,et al.A new histological grading system to assess response of breast cancers to primary chemotherapy:prognostic significance and survival[J].Breast,2003,12(5):320-327.
[5]Inagaki M,Ota D,Tsuji M,et al.Using ultrasound findings to predict high tumor-infiltrating lymphocytes in triple negative breast cancer[J].Cancer Res,2017,77(4 Suppl):40204.
[6]冯娅琴.彩色超声在乳腺癌患者新辅助化疗疗效评价中的应用价值[J].中华全科医学,2017,15(4):647-649.
[2]杨月杰.超声造影技术在乳腺癌新辅助化疗疗效评估中的应用分析[J].山西医药杂志,2019,48(2):40-41.
[3]贾志莺,张连花,马富成.超声联合技术在乳腺癌新辅助化疗疗效评价中的应用价值[J].医学影像学杂志,2017,27(9):1723-1725.
[4]Ogston KN,Miller ID,Payne S,et al.A new histological grading system to assess response of breast cancers to primary chemotherapy:prognostic significance and survival[J].Breast,2003,12(5):320-327.
[5]Inagaki M,Ota D,Tsuji M,et al.Using ultrasound findings to predict high tumor-infiltrating lymphocytes in triple negative breast cancer[J].Cancer Res,2017,77(4 Suppl):40204.
[6]冯娅琴.彩色超声在乳腺癌患者新辅助化疗疗效评价中的应用价值[J].中华全科医学,2017,15(4):647-649.